December 2, 2015New England Journal of Medicine110 citations
View Full PaperEstimating the Long-Term Treatment Benefits of Sacubitril–Valsartan
Key Result
Sacubitril-valsartan resulted in a mean of 1 to 2 additional years of survival compared with enalapril in patients with heart failure.
Structured PICO
Does sacubitril-valsartan improve survival in patients with heart failure compared with enalapril?
P
Population
Patients with heart failure (based on PARADIGM-HF trial data)
I
Intervention
Sacubitril-valsartan
C
Comparator
Enalapril
O
Outcome
Survival (additional years of survival)hard clinical
Actuarial modeling of PARADIGM-HF data suggests sacubitril-valsartan provides an estimated 1 to 2 additional years of survival compared to enalapril in heart failure patients.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
Using actuarial data based on the results of the PARADIGM-HF trial, investigators found that the use of sacubitril–valsartan in patients with heart failure resulted in a mean of 1 to 2 additional years of survival, as compared with enalapril.